or
Bookmark and Share
Alkoxy-4(1H)-pyridone derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
   
Document Number
US Patent 5185352
Issued Date
February 9, 1993
Link
Map
Abstract
The invention concerns new derivatives of certain alkoxy -4(1H)-pyridones, processes for preparing them, and pharmaceutical compositions containing them. The compounds of the invention are useful in the prevention and/or treatment of heart and blood vessel diseases such as thromboses, arteriosclerosis and hypertension, and of inflammatory processes, allergies, cancers, and certain degenerative damage of the central nervous system.
Drawing
Alkoxy-4(1H)-pyridone derivatives, processes for the preparation thereof and pharmaceutical compositions containing them - US Patent 5185352 Drawing
Drawing from US Patent 5185352
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
12
Comments:
no comments yet
Owner
Published
February 9, 1993
Application Number
07/640,407
Filed
January 28, 1991
US Classification
514/348   514/235.5 514/253.12 514/318 544/131 544/295 544/360 544/365 546/193 546/194 546/296 549/292
Int'l Classification
C07D   213/00   (20060101)   C07D   213/69   (20060101)   C07D   401/06   (20060101)   C07D   401/00   (20060101)  
Examiner
Assistant Examiner
Attorney/Law Firm
Priority Data
Aug 06, 1988 [DE] 3826846
USPTO Field of Search
546/296   514/348  
Related Patents
5849587 - Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells - Owned by Cornell Research Foundation, Inc. (Ithaca, NY)

The present invention is directed to methods which employ inhibition of the post-translational hypusine formation in the intracelluar protein eIF-5A, for the purpose of suppressing infections by viruses that parasitize eIF-5A so as to promote their own replication. Intentional inhibition of the post-translational formation of hypusine in infected host cells with compounds generically termed `hypusine inhibitors` not only selectively suppresses the production of viral proteins and of infectious viral particles, but also causes, particularly after hypusine inhibitor withdrawal, apoptosis in such virally-infected cells. Each of these methods, respectively, involves administering, to eukaryotic cells, tissues, or individuals, an agent which blocks the post-translational intracellular formation of hypusine, in an amount sufficient to: suppress biosynthesis of bioactive eIF-5A, suppress translational interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, inhibit biosynthesis of viral proteins of Rev-dependent lentiviruses or of viruses dependent on interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, inhibit replication of Rev-dependent lentiviruses or of viruses dependent on interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, and induce apoptosis of virally-infected cells. This agent can be a compound of Formulae I or II and derivatives thereof as follows: ##STR1## R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

5750555 - Bis-indolyl maleinimide or indolopyrrolo carbazole containing an amino acid as PKC inhibitors - Owned by Goedecke Aktiengesellschaft (Berlin,DE)

The instant invention is a compound of formula in which A is a bis-indolylmaleinimide or indolopyrrolocarbazole useful in the treatment and/or prevention of cancer, viral diseases, thrombosis, heart rhythm disturbances, atherosclerosis, bronchopulmonary diseases, degenerative diseases of the central nervous system, inflammatory diseases, diseases of the immune system, psoriasis, and immune suppression. A pharmaceutical composition and methods of preparing the compounds are also included.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us